Aflibercept as primary treatment for myopic choroidal neovascularisation: a retrospective study

@inproceedings{Bru2016AfliberceptAP,
  title={Aflibercept as primary treatment for myopic choroidal neovascularisation: a retrospective study},
  author={Claudia Bru{\`e} and Alfredo Pazzaglia and Cesare Mariotti and Michele Reibaldi and Alfonso Giovannini},
  booktitle={Eye},
  year={2016}
}
AimThe aim of this study is to evaluate long-term efficacy of intravitreal injections of aflibercept as primary treatment for subfoveal/juxtafoveal myopic choroidal neovascularisation (CNV).MethodsThirty-eight treatment-naive eyes of thirty-eight patients with subfoveal/juxtafoveal myopic CNV received initial intravitreal aflibercept injections and were followed for at least 18 months. Aflibercept was applied again for persistent or recurrent CNV, as required. Statistical analysis was carried… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 37 references

Intravitreal ranibizumab for the treatment of choroidal neovascularizations associated with pathologic myopia: a prospective study.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde • 2015

studies in wet age-related macular degeneration

JS Heier, D Boyer, +3 authors G Yancopoulos
Ophthalmology • 2015

Similar Papers

Loading similar papers…